SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED
- Country
- Ownership
- -
- Established
- 1998-11-20
- Employees
- 7K
- Market Cap
- -
- Website
- http://www.xhzy.com
- Introduction
The company was founded in 1943 at the Jiaodong anti-Japanese base. It is the first chemically synthesized pharmaceutical company in New China. It is an important global production and export base for antipyretic analgesics, and an important domestic manufacturer of cardiovascular, anti-infective, neurological, and steroidal hormone drugs. The company is mainly engaged in the development, manufacture and sale of chemical raw materials, formulations and chemical products. The company's main products are “Xinhua” antipyretic and analgesic drugs, cardiovascular, anti-infective and central nervous system drugs. Corporate honors: Advanced grass-roots party organizations for provincial management enterprises, enterprises that focus on cultivating century-old brands, list of the top 1000 innovative Chinese enterprises, etc.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
387
Drug Approvals
Isavuconazonium Sulfate for Injection
- Product Name
- 注射用硫酸艾沙康唑
- Approval Number
- 国药准字H20254347
- Approval Date
- May 27, 2025
Icosapent Ethyl Soft Capsules
- Product Name
- 二十碳五烯酸乙酯软胶囊
- Approval Number
- 国药准字H20254286
- Approval Date
- May 27, 2025
Icosapent Ethyl Soft Capsules
- Product Name
- 二十碳五烯酸乙酯软胶囊
- Approval Number
- 国药准字H20254287
- Approval Date
- May 27, 2025
Ibuprofen Suspension Drops
- Product Name
- 布洛芬混悬滴剂
- Approval Number
- 国药准字H20254095
- Approval Date
- May 13, 2025
Ibuprofen Suspension Drops
- Product Name
- 布洛芬混悬滴剂
- Approval Number
- 国药准字H20254094
- Approval Date
- May 13, 2025
Aspirin Enteric-coated Tablets
- Product Name
- 阿司匹林肠溶片
- Approval Number
- 国药准字H20258068
- Approval Date
- Apr 24, 2025
Memantine Hydrochloride Oral Solution
- Product Name
- 盐酸美金刚口服溶液
- Approval Number
- 国药准字H20253925
- Approval Date
- Apr 15, 2025
Pregabalin Oral Solution
- Product Name
- 普瑞巴林口服溶液
- Approval Number
- 国药准字H20253926
- Approval Date
- Apr 15, 2025
- Prev
- 1
- 2
- 3
- 4
- 5
- 39
- Next
Clinical Trials
News
Shandong Xinhua Pharma Gains Approval for Febuxostat Tablets in China
Shandong Xinhua Pharmaceutical's subsidiary, Shandong Zibo Xincat Pharmaceutical, has received approval from China's National Medical Products Administration for its febuxostat tablets.